Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.
MeSH: Muscular Atrophy, Spinal
Group: Other drugs for disorders of the musculo-skeletal system